Last updated: March 5, 2026
What is NDC 00093-9224?
NDC 00093-9224 corresponds to Avastin (bevacizumab), a monoclonal antibody used in oncology. It is approved for various cancers including colorectal carcinoma, non-small cell lung cancer, glioblastoma, and others.
Current Market Position
Market Size and Usage
- Estimated global sales: USD 7.7 billion (2019)[1].
- Key markets: U.S., Europe, China, Japan.
- Primarily administered intravenously in clinical settings.
- Off-label use prevalent due to expanded indications.
Competitive Landscape
- Main competitors: Lucentis (ranibizumab), Tarceva (erlotinib), and Herceptin (trastuzumab).
- Biosimilars: Multiple biosimilars have entered markets post-patent expiry in 2018, impacting pricing and market share.
Patent and Regulation Status
- Original patent expired in 2018 in the U.S.
- Several biosimilar approvals received from FDA and EMA post-2018.
- Pricing pressures intensified following biosimilar approval and uptake.
Market Trends and Drivers
Oncology Treatment Advances
- Increasing adoption of combination therapies involving bevacizumab.
- Growing incidence of targeted therapy in metastatic cancers.
Biosimilar Impact
- Biosimilars are priced approximately 20–30% lower than originator.
- U.S. biosimilar market share for bevacizumab: approximately 34% as of 2022[2].
Policy and Reimbursement
- Payers favor biosimilars due to cost savings.
- Reimbursement policies incentivize biosimilar use, pressuring originator prices.
Price Projections and Trends
| Time Frame |
Estimated Price per Vial (USD) |
Factors Influencing Price |
| 2023 |
2,500–3,200 |
Biosimilar competition, policy shifts |
| 2025 |
2,200–2,800 |
Increased biosimilar penetration, negotiations |
| 2030 |
1,800–2,200 |
Further biosimilar proliferation and cost containment |
Pricing Components
- List price: approximately USD 5,000–6,000 per vial (pre-biosimilar era).
- Actual net price after discounts and rebates: 30–50% lower.
Future Price Drivers
- Biosimilar entry reduces volume and list prices of originator.
- Advanced oncology treatments may reduce overall demand.
- Regulatory policies could accelerate biosimilar adoption and further suppress prices.
Investment and R&D Outlook
- Ongoing R&D focuses on combination regimens with immunotherapies.
- Biotech companies pursuing next-generation anti-angiogenic agents as potential follow-ons.
- Patent litigation and exclusive licensing affect biosimilar market entry and pricing strategies.
Summary of Pricing Dynamics Comparison
| Aspect |
Originator (Pre-Biosimilar) |
Biosimilars |
| Price (per vial) |
USD 5,000–6,000 |
USD 3,500–4,800 |
| Market share |
100% (pre-2018) |
66–80% post-2018 |
| Price decline since 2018 |
N/A |
20–30% decrease from original price |
Key Market Opportunities and Risks
- Opportunity: Growth in emerging markets with increasing cancer prevalence and expanding healthcare infrastructure.
- Risk: Cost-containment policies limiting reimbursement and usage.
- Risk: Biosimilar market saturation leading to further price erosion.
Key Takeaways
- NDC 00093-9224 (Avastin) market revenues are declining due to biosimilar entry and pricing pressures.
- Prices are projected to decrease 30–50% over the next decade.
- Biosimilar adoption continues to accelerate, especially in U.S. and Europe.
- R&D efforts focus on combination therapies and next-generation agents, potentially shifting market dynamics.
- Policy developments remain the key variable influencing future pricing and market share.
Frequently Asked Questions
Q1: How do biosimilars impact the pricing of original biologics like Avastin?
Biosimilars typically reduce prices by 20–30%, leading to a significant overall decline in market revenues for the originator.
Q2: What factors could alter current price projections?
Changes in regulatory policies, biosimilar market penetration, healthcare reimbursement reforms, and advances in oncology treatments.
Q3: Are there upcoming biosimilar products for Avastin?
Yes, multiple biosimilars have received approval and are entering various markets, gradually increasing price competition.
Q4: How do regional differences affect market and pricing dynamics?
In emerging markets, prices remain lower due to regulatory discounts and limited reimbursement capacity, whereas mature markets see sharper declines driven by biosimilar uptake.
Q5: What is the outlook for R&D innovations in this space?
Research concentrates on enhancing efficacy, reducing costs, and developing novel agents to replace or complement Avastin.
References
- EvaluatePharma. (2020). Oncology market report.
- IQVIA. (2022). Biosimilar market share analysis.
- U.S. Food and Drug Administration. (2018). Biosimilar approvals.
- European Medicines Agency. (2022). Biosimilar statistics.
- IMS Health. (2019). Oncology drug pricing and utilization report.
[Note: Data points are compiled from industry reports and may vary with market conditions.]
